Samil, Boehringer Ingelheim strengthens strategic alliance

Published: 2010-03-02 06:56:00

Updated: 2010-03-02 06:56:00

Samil Pharm said it has joined hands with Boehringer Ingelheim Korea to market Mirapex (pramipexole), a medication indicated for treating early-stage Parkinson’s disease and restless legs syndrome (RLS)

Samil has recently signed an exclusive distribution agreement with Boehringer Ingelheim Kor...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK